Safely Prescribing GLP-1 Medications for Older Adults: Remote care solutions that offer protection and connection
Remote care solutions, like connected devices and remote patient monitoring allow for safer GLP-1 use in older adults.
Part 3: Supporting Safe and Sustainable Weight Loss With GLP-1s – Managing weight after medication
Weight gain is likely when patients stop taking a GLP-1 therapy. A 2022 study found patients who took the GLP-1 semaglutide had regained two thirds of their prior weight and had similar cardiometabolic changes a year after stopping the medication. Prescribers at doctor’s offices and virtual weight loss programs should track patients throughout their journey and when they stop taking GLP-1s. This monitoring of daily progress provides long-term oversight of weight loss goals and maintenance.
Part 2: Supporting Safe and Sustainable Weight Loss With GLP-1s – Why body composition matters
GLP-1 agonists are remarkably effective in helping patients lose weight. But this can’t be done in a vacuum. One data point that’s often overlooked in a patient’s journey on GLP-1s is body composition.
Part 1: Supporting Safe and Sustainable Weight Loss With GLP-1s – Finding the right remote health technologies
New medications like GLP-1 agonists offer a promising tool to help patients achieve a healthy weight. But supporting patients in long-term weight loss involves more than medication.
Pioneering Real Change in Diabetes Care
Up to 70% of people with diabetes will be affected by diabetic peripheral neuropathy, and nearly half have no symptoms to alert them that it’s happening. This often silent condition increases the risk of foot ulcers and potential amputations. Patients with diabetic foot ulcers have a two-fold greater increase in mortality.